查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133478

全球静脉疾病治疗市场-2022-2029

Global Venous Diseases Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

静脉疾病治疗市场的增长受到静脉疾病患病率上升、对激光消融手术需求增加、静脉疾病治疗采用率上升、老年人口增加以及研究活动的推动。

静脉疾病患病率上升预计将推动市场增长。

各种静脉疾病的患病率上升，如血栓性深静脉血栓形成和慢性静脉功能不全，预计将在预测期内提振市场。 Bawakid 等人于 2021 年在麦加、吉达和达曼报告的一项研究提到，男性和女性慢性静脉功能不全的总体患病率为 45.6%。 2021 年在沙特阿拉伯地区卡西姆地区的一家初级卫生保健中心进行的一项患病率研究还显示，男性和女性的静脉曲张患病率为 61.1%。一项新的基于问卷的研究结合多普勒超声检查报告显示，韩国女性护士的静脉曲张患病率较低，为 16.18%。这可以归因于生活方式的快速变化和医疗保健的进步。对于静脉曲张患者，最常见的 CEAP 等级为 C1，表明本研究中女性的轻度疾病表现为毛细血管扩张或网状静脉。年龄也是我们体内静脉曲张发展和进展的主要风险因素。

年龄增长也是皮肤营养变化、血管内压力增加和浅静脉系统阳痿的重要因素。此外，在欧洲法国各地进行的一项大型研究报告称，72.7% 的孕妇患有静脉曲张。此外，较高的体重指数 (BMI) 与更晚期的静脉曲张有关。此外，通过生活方式的快速变化以及特别是通过社交媒体轻鬆获得医疗服务，人们对静脉曲张及其风险因素的认识不断提高，这推动了静脉疾病治疗市场的发展。

静脉疾病治疗费用高将阻碍市场增长

但是，静脉疾病治疗存在副作用，例如感染、疼痛和炎症、瘀伤、血栓和静脉消融期间的肿胀。此外，腿部和脚部的疼痛和沈重感，尤其是在长时间站立或行走后，以及腿部的烧灼感和抽筋，都是阻碍市场增长的因素。

COVID-19 影响分析

COVID-19 的出现对全球静脉疾病治疗市场产生了重大影响。根据 2020 年 7 月发表在 Sage Journal 上的一篇文章，COVID-19 大流行已经影响到关键供应、劳动力和医疗护理，例如为冠状病毒感染患者提供的急诊和重症监护室 (ICU) 设施，导致资源偏差。在美国和许多其他国家，外科手术已被推迟或取消，手术室资源一直集中在应对大流行病上。有限的直接个人接触和社交距离限制了获得治疗的机会。在大流行期间，患有静脉、淋巴或血管异常的患者发现难以获得专业护理。此外，越来越多的证据表明，患有动脉和静脉血栓栓塞 (VTE) 和广泛的凝血病的 COVID-19 在受影响的个体中更难以诊断。随着情况从 COVID-19 中恢復，更多接受静脉治疗的患者可以轻鬆获得适当的治疗，从而推动市场发展。

全球静脉疾病治疗市场报告将提供对大约 50 多个市场数据表、50 多个数字和 200 页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按治疗类型：市场细分
  • 按疾病类型：市场细分
  • 按产品类型：市场细分
  • 按最终用户：市场细分
  • 按分销渠道：市场细分
  • 按地区：市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 静脉疾病发病率上升
      • 加大研发力度
    • 约束因素
    • 与治疗药物相关的副作用
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 手术
  • 硬化疗法
  • 血管成形术或支架置入
  • 静脉结扎和剥离
  • 卡瓦过滤器
  • 门诊静脉曲张切除术
  • 射频消融治疗
  • 激光治疗
  • 其他治疗

第 8 章按疾病类型

  • 深静脉血栓性静脉炎
  • 静脉曲张和蜘蛛静脉
  • 浅表性血栓性静脉炎
  • 慢性静脉功能不全
  • 静脉溃疡
  • 其他

第 9 章按产品类型

  • 消融装置
  • 静脉支架
  • 静脉闭合
  • 硬化剂注射液
  • 其他

第 10 章，最终用户

  • 医院
  • 诊所
  • 门诊中心
  • 其他

第 11 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 14 章公司简介

  • Biolitec AG Untere Viaduktgasse
    • 公司概况
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • Teleflex Incorporated
  • BD
  • B. Braun Melsungen Ag
  • Alma Lasers
  • Becton Dickinson and Company
  • Koninklijke Philips N.V.

第 15 章全球静脉疾病治疗市场-DataM

简介目录
Product Code: DMPH5853

Market Overview

Venous Diseases Treatment Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

The venous disease includes blood clots in the legs, arms, brains, lungs, or internal organs (kidney, spleen, liver), deep vein thrombosis, chronic venous insufficiency, varicose and spider veins, and ulcers in the vein. The treatment for this disease includes drug therapy, endovenous laser ablation or radiofrequency ablation (RFA), sclerotherapy, and surgery.

Market Dynamics

The Venous Diseases Treatment market growth is driven by the rise in the prevalence venoous disease, rising demand for laser ablation procedures, rising adoption of venous diseases treatment, increase in the geriatric population, and research activities.

The increasing prevalence of venous diseases is expected to drive the market growth

The rising prevalence of different venous diseases such as blood clots deep vein thrombosis, and chronic venous insufficiency is expected to boost the market over the forecast period. In 2021, a study reported by Bawakid et al. in Makah, Jeddah and Dammam mentioned an overall prevalence of chronic venous insufficiency of 45.6% in both males and females. Also, a prevalence study conducted in 2021, in primary health care centers in Qassim region of Saudi Arabia region revealed that the prevalence of varicose veins among male and female was 61.1%. A new questionnaire-based study coupled with Doppler ultrasonography was showed in Republic of Korea reported less prevalence of varicose veins in female nurses 16.18%. This could be allocated to the rapid of changes in lifestyle and advancement in access to health care. Those people with varicose veins, the most commonly CEAP class was C1 which indicates a mild form of the disease presenting as telangiectasia or reticular veins among females in this study. In addition, age is a major contributing risk factor that rises the development and progression of varicose veins in our body.

Increasing in age is a significant factor in further skin trophic changes, growth in the endovascular pressure, and inability of the superficial venous system. Moreover, a large study done in different locations of France in Europe reported that 72.7% of pregnant women are suffering from varicose veins. Also, higher Body Mass Index (BMI) is associated to more advanced stages of varicose veins. Furthermore, fast changes in lifestyle and increased awareness about varicose veins and its risk factors through easier access to health care specifically through social media drives the venous disease treatment market.

The high cost of Venous Diseases Treatment will hamper the growth of the market

However, side effects associated with veous disease treatment such as infection during venous ablation, soreness and inflammation, bruising, blood clots and, swelling. In addition, pain and heaviness in the legs and feet, especially after long a time standing or walking for long periods of time and ,burning, and cramping in the legs restarestraintsmarket growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global venous diseases treatment market. As per the article published in Sage journals in July 2020, The COVID-19 pandemic has resulted in deviation of healthcare resources such as critical supplies, workforce, emergency and intensive care unit (ICU) facilities of patients infected with coronavirus. Interuuptions in surgical procedures in most countries such as United States had been postponed or cancelled and operating room resources were focused on management of the pandemic. Restrictions to direct personal contact and social distancing have controlled the access to care. Patients with venous and lymphatic disorders or vascular anomalies faced difficulty to get expert care in pandemic. In addition, there is increasing evidence that COVID-19 with both arterial and venous thromboembolic (VTE) disease and extensive coagulopathies is additionally difficult of the diagnosis of the affected patients. As the situation is recovering from COVID-19 more patients with venous treatment can easily access the proper treatment which drives the market.

Segment Analysis

The chronic venous insufficiency segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic venous insufficiency segment is expected to boost the market over the period of the forecast. In 2022, the article published in Dermatol Therpeutics, chronic venous disorder (CVD) is most prevalent vascular disorder affecting up to 45% of the general population, with clinical relevation ranging from teleangiectasias to venous leg ulcers. The prevalence of CVD rises with age and it is more familiar in female than male. However, estimates of CVD prevalence vary widely from study to study 15-80% due to differences in study design and target population, and most of time CVD is underdiagnosed and undertreated, especially at lower severity levels. The pharmacological treatment can give proper symptomatic relief and it is considered as part of conservative treatment. Transcutaneous Lacer treatment is a safe and effective alternative option to sclerotherapy for treatment of C1 stage. Ultrasound-guided foam sclerotherapy (UGFS), high ligation and stripping, endovenous thermal ablation (EVTA) systems and non thermal non tumescent ablation systems are safe and effective first-line options for treatment of saphenous insufficiency.

Furthermore, in january 2022, The European Society for Vascular Surgery (ESVS) has published 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 guidelines. The new guidelines foused on CVD of the lower limbs, related to pathology of the superficial, perforating and deep veins of the lower limb as well as to abdominal and pelvic venous pathology.

Geographical Analysis

North America region holds the largest market share of the global venous diseases treatment market

North America dominates the market for venous diseases treatment and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to technological advancement, presence of key players and easily availability of treatment. The article published in 2020 in J Vasc Surg Venous Lymphat Discord. Chronic venous insufficiency (CVI) resulting from venous reflux or obstruction leads to venous hypertension with edema, varicose veins, consequent pain, hyperpigmentation, and ulceration of the lower extremities. The CVI affects approximately 25 million adults in the United States region, with around 6 million suffering from advanced disease, and the annual cost of venous ulcer treatment and care is anticipated to be nearly $3 billion. Furthermore, for those people who are working for them CVI accounts for a loss of 2 million workdays per year, and almost 12% seek early retirement. Prolonged standing, Female sex, pregnancy, obesity; advanced lifestyle, venous reflux or obstruction, and deep venous thrombosis (DVT) are suspected risk factors for CVI. The increasing number of venous disease patient boosts the venous disease treatment market.

Competitive Landscape

The venous diseases treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Biolitec AG Untere Viaduktgasse, Teleflex Incorporated, B. Braun Melsungen Ag, Alma Lasers, Becton Dickinson and Company, and Koninklijke Philips N.V. among others. The major players are adopting several growth strategies such as treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the venous diseases treatment market globally.

For instance,

  • In February 2022, Becton, Dickison, and Company acquired Venclose Inc., a contributor of solutions for the treatment of chronic venous insufficiency (CVI) a disease that is the result of malfunctioning valves and can lead to varicose veins.

Becton, Dickison and Company

Overview:

The Becton, Dickinson and Company is an American multinational company that manufactures and distributes instrument systems, medical devices, and reagents for treatment of various diseases including venous disease.

Treatment Type Portfolio:

Venclose radiofrequency (RF) Ablation System: This system offers transformative solutions to improve outcomes in patients for chronic disease and able to the transition into novel care settings.

The global venous diseases treatment market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Treatment Type
  • 3.2. Market Snippet By Disease Type
  • 3.3. Market Snippet By Product Type
  • 3.4. Market Snippet By End User
  • 3.5. Market snippet By Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of venous diseases
      • 4.1.1.2. The increasing number of research and development activities
    • 4.1.2. Restraints:
    • 4.1.3. Side effects related to therapeutics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Surgeries*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Sclerotherapy
  • 7.4. Angioplasty or Stenting
  • 7.5. Vein Ligation and stripping
  • 7.6. Vena Cava Filter
  • 7.7. Ambulatory Phlebectomy
  • 7.8. Radiofrequency Ablation Therapy
  • 7.9. Laser Treatment
  • 7.10. Others Therapies

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Deep-vein Thrombophlebitis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Varicose and Spider Veins
  • 8.4. Superficial Thrombophlebitis
  • 8.5. Chronic Venous Insufficiency
  • 8.6. Venous Ulcers
  • 8.7. Others

9. By Product Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.1.2. Market Attractiveness Index, By Product Type
  • 9.2. Ablation Devices*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Venous Stents
  • 9.4. Venous Closure Products
  • 9.5. Sclerotherapy Injection
  • 9.6. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Centers
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Treatment type Benchmarking

14. Company Profiles

  • 14.1. Biolitec AG Untere Viaduktgasse*
    • 14.1.1. Company Overview
    • 14.1.2. Treatment type Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Teleflex Incorporated
  • 14.3. BD
  • 14.4. B. Braun Melsungen Ag
  • 14.5. Alma Lasers
  • 14.6. Becton Dickinson and Company
  • 14.7. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

15. Global Venous Diseases Treatment market- DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us